Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2025-12-25 @ 5:04 AM
NCT ID:
NCT00887718
Eligibility Criteria:
Group A: Newly Diagnosed
Inclusion Criteria:
* Patients \> 18 years of age.
* Confirmed diagnosis of HL or NHL (any histology).
* Any Ann Arbor stage.
* Pre-treatment staging including CT of head and neck, chest, abdomen and pelvis, where there is a minimum one equivocal finding on the scan, affecting the assignment of stage or IPI factor (i.e. stage III/IV vs. stage I/II, or a question of extranodal involvement by disease).
Group B: Response Assessment
Inclusion Criteria:
* Patients \> 18 years of age.
* Confirmed diagnosis of HL or NHL (any histology).
* Any Ann Arbor stage.
* Pre-treatment staging including CT neck, chest, abdomen and pelvis. If alternate assessment of the neck done by clinical palpitation, ultrasound, or MRI is negative, CT neck is not mandatory.
* Post-treatment staging including CT of head and neck, chest, abdomen and pelvis, at 1 - 6 weeks post-therapy.
* Treated with anthracycline-based chemotherapy, with or without radiation therapy (based on the stage of the disease). For Stage III/IV patients, PET will be done following completion of primary chemotherapy. For stage I/II patients, PET will be done after combined modality therapy, or after chemotherapy alone if this was the primary intention of therapy.
* Patients with residual mass on CT following primary chemotherapy with either "unconfirmed" CR (\>75% decrease in size) or PR (³50% decrease in size), based on International workshop criteria.
Exclusion Criteria: Response Assessment
* None Curative treatment Intent
* After initial therapy the response status is: complete response, stable disease, or progressive disease
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00887718
Study Brief:
Protocol Section:
NCT00887718